Roche (ROG) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
22 Oct, 2026Executive summary
H1 sales rose 6% at CER to CHF 30,364m, but fell 2% in CHF as Swiss franc appreciation weighed on reported results.
Core operating profit increased 10% at CER and Core EPS rose 9%; both Pharma and Diagnostics grew at CER.
Five FDA Priority Reviews and positive phase III results marked strong pipeline progress.
Financial highlights
Core operating profit was CHF 11,856m, up 10% at CER; Core EPS was CHF 10.85, up 9% at CER. Both declined in CHF, by 1% and 2%, respectively.
IFRS net income was CHF 7,325m, down 6% in CHF but up 6% at CER; Core net income rose 11% at CER.
Operating free cash flow reached CHF 6,264m, up 21% at CER; free cash flow was CHF 4,197m, up 58% at CER and 26% in CHF.
IFRS operating profit was CHF 9,671m, down 6% in CHF and up 6% at CER; non-core operating items totaled CHF 2,185m.
Outlook and guidance
2026 guidance confirmed: mid-single-digit sales growth and high-single-digit Core EPS growth at CER.
Expected 2026 LOE impact is ~CHF 0.6bn, including losses of Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra.
Further dividend growth in Swiss francs expected; significant pipeline readouts include Itovebi, Lunsumio, sefaxersen and obesity programs.
Latest events from Roche
- CER sales grew 7%; new products and COVID testing offset currency and pandemic pressures.ROG
Q1 2020 - CER growth persisted as new medicines and COVID-19 testing offset pandemic disruption.ROG
H1 2020 - Diagnostics and new products offset pandemic and biosimilar pressure; 2021 growth targets remain intact.ROG
H2 2020 - Diagnostics-led growth and stronger cash flow offset Pharma pressure; FY guidance held.ROG
H1 2021 - Diagnostics and new medicines offset biosimilars and pandemic disruption as guidance held.ROG
Q3 2020 - Diagnostics-led growth lifted sales 8% at CER and prompted higher FY guidance.ROG
Q3 2021 - Diagnostics growth offset Pharma declines; FY 2021 guidance was reaffirmed.ROG
Q1 2021 - Strong Diagnostics and new products lifted sales 9% at CER despite biosimilar erosion.ROG
H2 2021 - Sales rose 11% at CER as both divisions grew despite AHR erosion and currency headwinds.ROG
Q1 2022 - Nine-month sales rose 6.2% at CER, led by Pharma growth and pipeline progress.ROG
Q3 2026